Mosapride is a gastroprokinetic abettor that acts as a careful 5HT4 agonist. The above active metabolite of mosapride, accepted as M1, additionally acts as a 5HT3 antagonist, which accelerates belly elimination throughout the accomplished of the gastrointestinal amplitude in humans, and is used for the analysis of gastritis, gastroesophageal abatement disease, anatomic dyspepsia and annoyed bowel syndrome. It is recommended to be taken on an abandoned stomach.
In accession to its prokinetic properties, mosapride aswell exerts anti-inflammatory furnishings on the gastrointestinal amplitude which may accord to some of its ameliorative effects. Mosapride aswell promotes neurogenesis in the gastrointestinal amplitude which may prove advantageous in assertive bowel disorders. The neurogenesis is due to mosapride’s aftereffect on the 5-HT4 receptor area it acts as an agonist.
Its accepted side effects cover dry mouth, belly pain, dizziness, headache, insomnia, malaise, nausea, diarrhea and sometimes constipation. Unlike some added prokinetic agents, mosapride has little aftereffect on potassium channels, no aftereffect on hERG transfected cells, and no aftereffect on cardiovascular action that could be detected in tests on humans. Due to the pharmacokinetics of mosapride, it would yield 1,000–3,000 times the ameliorative dosage to arm-twist cardiovascular effects.